Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 48 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

33%

16 trials in Phase 3/4

Results Transparency

17%

5 of 30 completed with results

Key Signals

5 with results100% success

Data Visualizations

Phase Distribution

36Total
Not Applicable (8)
Early P 1 (2)
P 1 (6)
P 2 (4)
P 3 (7)
P 4 (9)

Trial Status

Completed30
Unknown10
Recruiting5
Not Yet Recruiting2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 30 completed trials

Clinical Trials (48)

Showing 20 of 20 trials
NCT06682117Not ApplicableRecruiting

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

NCT05765773Phase 2Completed

An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older

NCT07135453Phase 4Not Yet RecruitingPrimary

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

NCT06588530Phase 4Completed

PFAS Exposure and Immune Response to Vaccination in Adults

NCT04543877Early Phase 1Completed

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study

NCT04083950Early Phase 1Active Not Recruiting

Induction of Gut Permeability by an Oral Vaccine

NCT05099965Phase 2Completed

Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

NCT06128928Not ApplicableRecruiting

Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities

NCT06799013Phase 1RecruitingPrimary

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

NCT07078357Phase 1Not Yet Recruiting

Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor

NCT06136832Not ApplicableCompleted

Pneumonia Vaccine Education Intervention Study

NCT04460235Phase 4RecruitingPrimary

Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

NCT07016152Phase 1Recruiting

An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults

NCT04741828Phase 2CompletedPrimary

Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian

NCT05752747Not ApplicableCompletedPrimary

The Effect of Shotblocker and Cold Massage on Pain, Crying Time and Physiological Parameters in Babies

NCT06813729Phase 4Completed

Effects of Shotblocker® and Manual Pressure on Pain

NCT05054621Phase 2Completed

Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

NCT06450379CompletedPrimary

Impact of Vaccines on Antimicrobial Microbial Resistance

NCT04573205Phase 4Unknown

Primary TBE Vaccination for the Elderly

NCT04843917Completed

Immunity Against COVID-19 Vaccine in Healthcare Workers in Argentine

Scroll to load more

Research Network

Activity Timeline